Disseminated Coccidioidomycosis Risk Factors

Immunologic Basis

The increased prevalence of disseminated coccidioidomycosis in individuals of African or Filipino descent is thought to be predominantly due to differences in immunologic responses to infection, though the exact mechanisms remain incompletely understood 1, 2
Specific gene mutations affecting interferon-γ, interleukin-12 (IL-12), and other cellular immune pathways can dramatically increase dissemination risk to as high as 75% (compared to the typical 1% risk) 1, 2, 3

For persons of Caucasian ancestry, extrapulmonary dissemination occurs in approximately 0.5% of infections 4, 5
For persons of African or Filipino ancestry, this risk is "several-fold higher" 4, 5
Severe immunosuppression (HIV, transplant recipients, high-dose corticosteroids) is associated with a 30-50% dissemination risk 6, 7

The IDSA guidelines state that male sex, African or Filipino ancestry, and diabetes are significant risk factors, but "they do not carry nearly the same degree of heightened risk" as severe immunosuppression and "only modestly should influence management decisions" 1, 2, 8, 3
Severe immunosuppression (HIV, transplant, TNF inhibitors, high-dose corticosteroids) is a key risk factor that should drive treatment decisions, with a dissemination risk up to 75% 6, 1, 3
The Infectious Diseases Society of America (IDSA) guidelines recommend considering ancestry in risk assessment, but it should only modestly influence management decisions 1, 2, 8, 3

The Caucasian ancestry is associated with approximately 0.5% risk of extrapulmonary dissemination, according to the Infectious Diseases Society of America guidelines 9, 10
Filipino ancestry is associated with a "several-fold higher" risk of dissemination than Caucasian ancestry, with one study showing 30% of Filipino patients with pulmonary disease progressed to disseminated disease 9

Patients of mixed ancestry should be monitored more closely than pure Caucasian patients, with serial clinical evaluations every 3-6 months for up to 2 years, as recommended by the Clinical Infectious Diseases guidelines 9